Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized phase II study of zoledronate dosing every four versus eight weeks in patients with bone metastasis from lung cancer (Hanshin Cancer Group0312).
Katakami N, Nishimura T, Hidaka Y, Hata A, Nishino K, Mori M, Hirashima T, Takase N, Kaneda T, Ohnishi H, Morita S, Hatachi Y. Katakami N, et al. Among authors: takase n. Lung Cancer. 2023 Aug;182:107261. doi: 10.1016/j.lungcan.2023.107261. Epub 2023 May 26. Lung Cancer. 2023. PMID: 37307753 Clinical Trial.
Comprehensive serum biomarker analysis reveals IL-8 changes as the only predictor of the effectiveness of immune checkpoint inhibitors for patients with advanced non-small cell lung cancer.
Akamatsu H, Koh Y, Nishio M, Goto Y, Hayashi H, Miura S, Tamada K, Kagamu H, Gemma A, Yoshino I, Misumi T, Mouri A, Saito R, Takase N, Yanagitani N, Nokihara H, Seike M, Takamura K, Mori M, Iwasawa S, Nakagawa S, Mitsudomi T. Akamatsu H, et al. Among authors: takase n. Lung Cancer. 2024 Dec;198:108017. doi: 10.1016/j.lungcan.2024.108017. Epub 2024 Nov 9. Lung Cancer. 2024. PMID: 39571250 Free article.
Association between Immune-Related Adverse Events and Atezolizumab in Previously Treated Patients with Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.
Hayashi H, Nishio M, Akamatsu H, Goto Y, Miura S, Gemma A, Yoshino I, Misumi T, Kijima T, Takase N, Fujita M, Tasaka S, Mouri A, Kondo T, Takamura K, Kawashima Y, Imaizumi K, Iwasawa S, Nakagawa S, Mitsudomi T. Hayashi H, et al. Among authors: takase n. Cancer Res Commun. 2024 Nov 1;4(11):2858-2867. doi: 10.1158/2767-9764.CRC-24-0212. Cancer Res Commun. 2024. PMID: 39392339 Free PMC article.
Trial Protocol of a Phase II Study of mFOLFOXIRI after Metastasectomy in Patients with Oligometastatic Colorectal Cancer (FANTASTIC Study).
Kataoka K, Yamada T, Yamazaki K, Mori K, Matsuhashi N, Shiozawa M, Iwai T, Goto M, Yasui M, Takii Y, Suto T, Takamizawa Y, Takase N, Sharma S, Ensor J, Jurdi A, Liu MC, Ikeda M, Kanemitsu Y. Kataoka K, et al. Among authors: takase n. J Anus Rectum Colon. 2024 Jul 30;8(3):246-252. doi: 10.23922/jarc.2024-025. eCollection 2024. J Anus Rectum Colon. 2024. PMID: 39086881 Free PMC article.
Monitoring ctDNA RAS Mutational Status in Metastatic Colorectal Cancer: A Trial Protocol of RAS-trace and RAS-trace-2 Studies.
Kataoka K, Yamada T, Shiozawa M, Takase N, Ito K, Yamazaki K, Watanabe J, Kudo T, Suto T, Matsumoto T, Murata K, Suwa Y, Boku S, Yasui H, Matsuhashi N, Maeda A, Sugimoto K, Matsumoto Y, Yokota M, Fredebohm J, Mori K, Ikeda M. Kataoka K, et al. Among authors: takase n. J Anus Rectum Colon. 2024 Apr 25;8(2):132-136. doi: 10.23922/jarc.2023-051. eCollection 2024. J Anus Rectum Colon. 2024. PMID: 38689780 Free PMC article.
83 results